{"id":1370,"date":"2021-08-24T05:29:36","date_gmt":"2021-08-24T05:29:36","guid":{"rendered":"https:\/\/ultimatehealthreport.com\/the-fda-defers-to-pharma-nixes-cbd-as-dietary-supplement\/"},"modified":"2021-08-24T05:29:36","modified_gmt":"2021-08-24T05:29:36","slug":"the-fda-defers-to-pharma-nixes-cbd-as-dietary-supplement","status":"publish","type":"post","link":"https:\/\/ultimatehealthreport.com\/the-fda-defers-to-pharma-nixes-cbd-as-dietary-supplement\/","title":{"rendered":"The FDA Defers to Pharma, Nixes CBD as Dietary Supplement"},"content":{"rendered":"


\n<\/p>\n

\n

On Aug 12, the FDA<\/span> formally rejected two New Dietary Ingredient (NDI<\/span>) applications seeking to establish CBD<\/span> as a lawful dietary supplement. Apparently, the fix was in from the start. The FDA<\/span> never intended to approve the applications by Charlotte\u2019s Web, a pioneer CBD<\/span> brand, and Irwin Naturals, a legacy supplement company that has jumped into the CBD<\/span> space.<\/p>\n

Although millions of doses of CBD<\/span> have been consumed in the United States, the FDA<\/span> claims it has insufficient data to assess if there\u2019s a dosage of CBD<\/span> that\u2019s safe for consumers. Irrespective of real or imagined safety concerns, it seems that the FDA<\/span> was committed to delivering a predetermined thumbs-down verdict in keeping with the \u201cexclusionary clause\u201d of the 1994 Food Drug and Cosmetic Act, whereby supplements can\u2019t contain pharmaceutical ingredients.<\/p>\n